Tags

Type your tag names separated by a space and hit enter

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vaccine. 2009 Oct 23; 27(45):6291-5.V

Abstract

After priming with two intramuscular doses of MF59-adjuvanted (Sub/MF59) or split influenza vaccines during the 2006/07 season, 89 healthy children received a third booster dose of the respective vaccine (2007/08 Northern Hemisphere formulation) approximately 1 year later, and were followed up for 6 months post-third injection. Immunogenicity was evaluated on 81 of them by a hemagglutination inhibition (HI) assay before and 3 weeks after vaccination. The Sub/MF59 influenza vaccine was safe and well tolerated following the booster vaccination. Pre-booster HI antibody titers were consistently higher in the Sub/MF59 group than in the comparator group, confirming significantly longer persistence of antibodies after priming with Sub/MF59 vaccine. Post-booster immune responses were significantly higher in the Sub/MF59 group compared with the split group, especially vs. the influenza B strain, which is epidemiologically relevant in the pediatric population. Altogether, these data further support the potential use of MF59-adjuvanted influenza vaccine as a safe and highly immunogenic influenza vaccine for young children.

Authors+Show Affiliations

University of Tampere Medical School, Medical School/FM3, 33014 Tampere, Finland. timo.vesikari@uta.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19840662

Citation

Vesikari, T, et al. "MF59-adjuvanted Influenza Vaccine (FLUAD) in Children: Safety and Immunogenicity Following a Second Year Seasonal Vaccination." Vaccine, vol. 27, no. 45, 2009, pp. 6291-5.
Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine. 2009;27(45):6291-5.
Vesikari, T., Groth, N., Karvonen, A., Borkowski, A., & Pellegrini, M. (2009). MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine, 27(45), 6291-5. https://doi.org/10.1016/j.vaccine.2009.02.004
Vesikari T, et al. MF59-adjuvanted Influenza Vaccine (FLUAD) in Children: Safety and Immunogenicity Following a Second Year Seasonal Vaccination. Vaccine. 2009 Oct 23;27(45):6291-5. PubMed PMID: 19840662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. AU - Vesikari,T, AU - Groth,N, AU - Karvonen,A, AU - Borkowski,A, AU - Pellegrini,M, PY - 2008/11/19/received PY - 2009/01/25/revised PY - 2009/02/02/accepted PY - 2009/10/21/entrez PY - 2009/10/21/pubmed PY - 2009/12/16/medline SP - 6291 EP - 5 JF - Vaccine JO - Vaccine VL - 27 IS - 45 N2 - After priming with two intramuscular doses of MF59-adjuvanted (Sub/MF59) or split influenza vaccines during the 2006/07 season, 89 healthy children received a third booster dose of the respective vaccine (2007/08 Northern Hemisphere formulation) approximately 1 year later, and were followed up for 6 months post-third injection. Immunogenicity was evaluated on 81 of them by a hemagglutination inhibition (HI) assay before and 3 weeks after vaccination. The Sub/MF59 influenza vaccine was safe and well tolerated following the booster vaccination. Pre-booster HI antibody titers were consistently higher in the Sub/MF59 group than in the comparator group, confirming significantly longer persistence of antibodies after priming with Sub/MF59 vaccine. Post-booster immune responses were significantly higher in the Sub/MF59 group compared with the split group, especially vs. the influenza B strain, which is epidemiologically relevant in the pediatric population. Altogether, these data further support the potential use of MF59-adjuvanted influenza vaccine as a safe and highly immunogenic influenza vaccine for young children. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/19840662/MF59_adjuvanted_influenza_vaccine__FLUAD__in_children:_safety_and_immunogenicity_following_a_second_year_seasonal_vaccination_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(09)00213-8 DB - PRIME DP - Unbound Medicine ER -